CD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program

CD28 superagonist (CD28SA), a therapeutic immunomodulatory monoclonal antibody triggered rapid and exaggerated activation of CD4(+) effector memory T cells (T(EMs)) in humans with unwanted serious adverse effects. It is well known that distinct metabolic programs determine the fate and responses of...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Monoclon Antib Immunodiagn Immunother
Auteurs principaux: Thaventhiran, Thilipan, Wong, Wai, Alghanem, Ahmad F., Alhumeed, Naif, Aljasir, Mohammad A., Ramsey, Simeon, Sethu, Swaminathan, Yeang, Han Xian Aw, Chadwick, Amy E., Cross, Michael, Webb, Steven D., Djouhri, Laiche, Ball, Christina, Stebbings, Richard, Sathish, Jean G.
Format: Artigo
Langue:Inglês
Publié: Mary Ann Liebert, Inc., publishers 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6634261/
https://ncbi.nlm.nih.gov/pubmed/31009338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/mab.2018.0042
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires